Literature DB >> 12643009

Differentiating solitary pulmonary metastases in patients with extrapulmonary neoplasmas using FDG-PET.

Wu-Huei Hsu1, Nan-Yung Hsu, Yeh-You Shen, Ruoh-Fang Yen, Chia-Hung Kao.   

Abstract

The purpose of this preliminary study is to evaluate the characteristics of solitary pulmonary lesions in patients using extrapulmonary neoplasmas with 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET). Thirty-two patients with extrapulmonary neoplasmas who had solitary pulmonary lesions and were suspected for pulmonary metastasis underwent an oncological survey with FDG-PET. Standard uptake value (SUV) and the ratio of lesion-to-background (L/B ratio) were used as parameters to differentiate and characterize the solitary pulmonary lesions. Using SUV > 2.5 or L/B ratio > 3 as the cutoff to diagnose malignancy, FDG-PET correctly identified 29 true-positive cases. However, FDG-PET failed to interpret two false-positive and one false-negative cases. The accuracy of FDG-PET was 91%. We concluded that FDG-PET is an accurate modality to differentiate solitary pulmonary lesions in patients with extrapulmonary neoplasmas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12643009     DOI: 10.1081/cnv-120016403

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  3 in total

1.  Correlation of tissue biopsy and fine needle aspiration cytology with positron emission tomography results.

Authors:  Daniel Rosen; Bruce Herrington; Peeyush Bhargava; Rodolfo Laucirica; Gordana Verstovsek
Journal:  Patholog Res Int       Date:  2011-04-06

2.  FDG PET Appearance of "Cannonball" Pulmonary Metastases.

Authors:  Murali Meka; Srinivas Bommireddipalli; Jonathan Killam; Peeyush Bhargava; E Gordon Depuey
Journal:  Radiol Case Rep       Date:  2015-12-07

3.  The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC.

Authors:  A D Nygaard; P C Holdgaard; K-L G Spindler; N Pallisgaard; A Jakobsen
Journal:  Br J Cancer       Date:  2013-11-14       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.